Boston Scientific stock rating reiterated at Overweight by Piper Sandler

Boston Scientific (NYSE:BSX) is experiencing mixed analyst sentiment following its recent analyst day, despite projecting significant growth, including 14-15% sales growth for 2025 and over 10% organic sales growth with double-digit EPS growth for 2026-2028. Firms like Piper Sandler and RBC Capital maintain positive ratings, citing robust LTM revenue growth of 21.44% and upcoming catalysts such as the IVL rollout and strength in its electrophysiology franchise. However, concerns persist regarding potential deceleration and increased competition in the Pulsed Field Ablation (PFA) business from 2025-2027, prompting Erste Group to downgrade the stock to Hold due to its high price-to-earnings ratio.

Analysis

Boston Scientific (BSX) presents a compelling growth outlook, supported by strong financial guidance and a robust product pipeline, though it is tempered by valuation concerns and anticipated competitive pressures. The company has demonstrated significant historical performance with 21.44% revenue growth over the last twelve months and has issued ambitious targets, projecting 14-15% sales growth for 2025 and a long-range plan for 2026-2028 that includes over 10% organic sales growth and double-digit EPS growth. This outlook is bolstered by a series of upcoming growth catalysts, including the intravascular lithotriopsy (IVL) rollout in 2025 and the launches of Therasphere, SonoVie, and Vitalyst by 2027. Consequently, analyst sentiment is largely positive, with firms like Piper Sandler, RBC Capital, and Stifel reiterating Buy-equivalent ratings. However, there are notable headwinds. Investors are reportedly concerned about a potential deceleration in the Pulsed Field Ablation (PFA) business and rising competition in that segment from 2025. This, combined with a high price-to-earnings ratio, prompted a downgrade from Erste Group to 'Hold', creating a clear divergence in analyst perspectives and highlighting the tension between the company's strong growth narrative and its premium valuation.

Key Decisions for Investors

• Given the strong multi-year growth guidance and deep product pipeline, investors with a long-term horizon could consider the stock's recent flat performance a potential entry point, aligning with the majority of analyst 'Buy' ratings.
• Investors should closely monitor competitive developments and revenue trends within the Pulsed Field Ablation (PFA) segment, as the forecasted deceleration from 2025 is a primary articulated risk to the company's growth trajectory.
• With a high P/E ratio being a point of contention, the upcoming earnings report on October 22, 2025, and results from the Watchman device's Champion trial are critical near-term catalysts that must be watched to justify the current valuation.